PODCAST · health
MIB Agents OsteoBites and osTEAo
by MIB Agents Osteosarcoma
Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org
Episodes
-
osTEAo: Spooky Sarcoma Stories
In this special Halloween episode of osTEAo, Sammy, Inaaya, Elise, Camille, and Sabina share some of the scariest and most unexpected moments of their osteosarcoma journeys. From unexpected side effects to frightening experiences during treatment, OsteoWarriors reflect on the challenges that can...
-
A Phase 1 Trial evaluating Folate Receptor Alpha CAR T cells for Advanced Osteosarcoma
Dr. Michelle Choe will introduce a phase 1 clinical trial currently open at Fred Hutch Cancer Center for folate receptor alpha (FOLR1)-CAR T cells for pediatric and adult patients with relapsed/refractory osteosarcoma after front-line therapy. This clinical trial is currently actively accruing…
more -
MISTOSUS: A phase II clinical trial of IscadorP (Mistletoe extract) as immunotherapy to improve event-free survival in patients with relapsed resectable osteosarcoma
There is an urgent need for safe and effective therapies to improve outcomes for patients with relapsed osteosarcoma. Viscum album extract (Iscador P, Iscador AG, Arlesheim, Switzerland) is a mistletoe extract manufactured from the leaves, stems and berries of Viscum album L., grown on pine trees...
-
osTEAo: Let's Talk Childhood Cancer
This month on osTEAo, Sammy, Inaaya, Mackenzie, and Keely discuss Childhood Cancer Awareness Month, how childhood cancer is portrayed and understood, and what those portrayals can miss about the realities of a cancer diagnosis. They share personal experiences and perspectives on awareness,...
-
A Phase 1b Study of Tegavivint, a TBL1 Inhibitor, with Gemcitabine in Patients with Relapsed or Refractory Osteosarcoma (TIGER)
Osteosarcoma Webinar Series: W. Thomas Cash, MD, MSc Children's Healthcare of Atlanta will discuss his work the TIGER study, which is a phase 1 study testing the TBL1 inhibitor tegavivint in combination with gemcitabine for pediatric and AYA patients with relapsed or refractory osteosarcoma. The...
-
CCDI Data Ecosystem in Action: Enabling Data-Driven Discovery
Osteosarcoma Webinar Series: Subhashini Jagu, PhD, from the National Cancer Institute, joins us on OsteoBites to discuss the Childhood Cancer Data Initiative. This presentation highlights how the Childhood Cancer Data Initiative (CCDI) Data Ecosystem is transforming pediatric cancer research by...
-
Functional Precision Medicine for Osteosarcoma
The Greenfield Lab’s long-standing research interests focus on basic and translational aspects of bone biology, and on osteosarcoma metastasis. The osteosarcoma project aims to repurpose FDA-approved drugs to block growth of lung metastases, which is the primary cause of lethality in osteosarcoma...
-
osTEAo: Same Summer, Different View
This episode of osTEAo features OsteoWarriors Inaaya, Sloane, and Elise sharing their experiences adapting summer activities and travel with limb differences. They discuss everything from summer camp, swimming, and ziplining to navigating theaters, airports, and public transportation. The...
-
Dissecting and Targeting Metastatic Drivers in Osteosarcoma
Metastatic osteosarcoma remains a major clinical challenge, highlighting the need to better understand the molecular mechanisms that drive disease progression. In this talk, Moreno will present the use of an in vivo CRISPR interference (CRISPRi) screen to identify genes that promote osteosarcoma...
-
Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis
Dr. Alexander Davies discusses his OutSmarting Osteosarcoma-funded work on the validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis, funded Because of Matthew, in partnership with Fishin' for the Cure.
-
Combinatorial immunotherapy to overcome cellular therapy resistance in osteosarcoma
Osteosarcoma Webinar Series: Jeremy Rosenblum, MD from New York Medical College will discuss his work on combinational next generation CAR NK immunotherapy in osteosarcoma. Immunotherapeutic approaches to treating osteosarcoma have had limited success to date. Using natural killer cells as the…
more -
Epigenetic Regulation of the Type I Interferon Pathway in Osteosarcoma: Implications for Immune Checkpoint Blockade
Osteosarcoma Webinar Series: Dr. Jing Huang is a Senior Investigator and Head of the Cancer and Stem Cell Epigenetics Group in the Laboratory of Cancer Biology and Genetics at the National Cancer Institute (NCI). He received his bachelor’s degree in Biochemistry from Peking University and his…
more -
osTEAo: Live from FACTOR '26!
Recorded live at FACTOR 2026, this episode of osTEAo features conversations with OsteoWarriors, OsteoSiblings, parents and family members, as well as the behind-the-scenes volunteers and staff who help make FACTOR possible. Guests share their experiences, favorite memories, and what this…
more -
osTEAo: Advocacy Doesn't End at Discharge
In this episode of osTEAo, Sammy and Inaaya are joined by Elise, Sloane, and Camille for a conversation about self-advocacy and how it evolves after an osteosarcoma diagnosis. The group shares personal experiences navigating college, careers, travel, accessibility, and everyday life as survivors...
-
Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma
Osteosarcoma Webinar Series: Barbara VanHare from the Rare Cancer Research Foundation will discuss the key role patients can play in accelerating Osteosarcoma breakthroughs through the donation of excess tissue and clinical data. She will walk through current barriers in rare cancer research, why...
-
A Guide to FACTOR 2026 Scientific Panels
Matteo Trucco, MD, joins us on OsteoBites to break down the scientific panels featured at the 2026 FACTOR conference. From clinical trials to the latest advances in osteosarcoma research, Dr. Trucco will guide attendees through the key themes and conversations shaping FACTOR 2026. Whether you are...
-
osTEAo - More Than Physical: The Mental Toll of Cancer
In this episode of osTEAo, OsteoWarriors share honest and personal reflections on the mental health challenges that can come with diagnosis, treatment, surgery, and survivorship. They talk about the fear, isolation, and loss of normalcy that often come with cancer, especially as young people…
more -
A Phase 1/2, Study to Evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in Patients with Relapsed/Refractory Osteosarcoma
David Shulman, MD, joins us on OsteoBites to discuss the newly opened phase 1/2 study to evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in patients with relapsed/refractory osteosarcoma. For many years, LRRC15 has been known to be an important target in osteosarcoma. A prior study...
-
Defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma
Andrew Clugston, PhD, a postdoctoral fellow in the Sweet-Cordero Lab at UCSF joins us on OsteoBites to discuss his OutSmarting Osteosarcoma funded work, in partnership with the RISE Foundation, on defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma.…
more -
Targeting Perioperative Myeloid Responses Through NOD/RIPK2 Modulation to Prevent Metastatic Progression in Osteosarcoma
OsteoBites welcomes Caroline Maloney, MD, PhD, from the Medical College of Wisconsin, who will discuss her research on surgery-accelerated metastasis and developing perioperative therapies. Pulmonary metastasis remains the major cause of death in osteosarcoma. The timing of metastatic relapse...
-
osTEAo: The Sound of Strength
In this episode of osTEAo, the group explores how music is a powerful tool for coping with cancer - helping patients process emotions, find comfort during treatment, and stay connected to themselves and others. From meaningful song interpretations to personal stories of healing, the conversation...
-
Zanzalintinib in Osteosarcoma: Balancing Disease Control and Quality of Life
Philippos A. Costa, MD joins us on OsteoBites to introduce a Phase 2 clinical trial of zanzalintinib for people with osteosarcoma. The study is intended for patients who cannot receive standard chemotherapy or whose cancer has not responded to available treatments. The goal is to explore whether...
-
Extracellular Matrix Degradation to Overcome Osteosarcoma Chemoresistance
The Rao Lab at Seattle Children's Research Institute developed a three-dimensional (3D) tissue-engineered model of osteosarcoma to investigate the effects of the extracellular matrix on malignant cell function. The study demonstrated that culturing osteosarcoma (OS) cells within a 3D collagen...
-
Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma
Osteosarcoma Webinar Series: Ali Cihan, PhD, a research scholar at Memorial Sloan Kettering Cancer Center, will discuss his OutSmarting Osteosarcoma funded work on targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma. Dr. Ali Cihan is a research scholar at...
-
Identifying mechanisms of chemoresistance in metastatic osteosarcoma using molecular barcoding
Dr. Aafrin Pettiwala from UCSF joins us on OsteoBites to discuss her OutSmarting Osteosarcoma funded work on identifying mechanisms of chemoresistance in metastatic osteosarcoma using molecular barcoding. The presentation covers how intratumoral heterogeneity drives chemoresistance and metastasis...
-
New insights into shared molecular and genomic features between humans and dogs with OS
Amy LeBlanc, DVM, a board-certified veterinary oncologist, Senior Scientist, and the Director of the intramural NCI’s Comparative Oncology Program, will review canine osteosarcoma and the clinical, biologic, and molecular features that make it a relevant animal-patient model for humans. She will...
-
Implementing personalized, adaptive therapies in osteosarcoma
Osteosarcoma Webinar Series: Corey Weistuch, PhD, an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center, will discuss his OutSmarting Osteosarcoma funded work on implementing personalized,...
-
osTEAo: The Sibling Side of Cancer
This episode of osTEAo focuses on the sibling side of cancer—celebrating the strength and support siblings bring to their families, and uplifting those who have lost a sibling and continue showing up every day. As the family focuses shift toward treatment and recovery, siblings often carry things...
-
High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches
Osteosarcoma Webinar Series: David Ulmert, MD, PhD, an Associate Professor at UCLA, discusses his OutSmarting Osteosarcoma funded work (Because of Sydney) on high-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover...
-
osTEAo: New Year, Same Cancer
The first episode of 2026 keeps it real about what the New Year actually feels like when osteosarcoma is still part of everyday life. Mia and Sammy are joined by Sloane and Mackenzie to talk through pain, recovery, scans, insurance stress, and the emotional weight January can bring. There’s no...
-
Next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma
Osteosarcoma Webinar Series: Joseph Skeate, PhD, an Assistant Professor at the University of Minnesota, discusses his OutSmarting Osteosarcoma funded work (Because of Annaleigh) on next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma. In this presentation, Dr....
-
Insights from the Musculoskeletal Tumor Society (MSTS) December 2025 Annual Meeting
Osteosarcoma Webinar Series: Izuchukwu Ibe, MD, a musculoskeletal oncologist, Associate Professor, and Residency Program Director at the University of Mississippi Medical Center joins us on OsteoBites to discuss insights and highlights from the Musculoskeletal Tumor Society (MSTS) December 2025...
-
Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma
Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma Osteosarcoma Webinar Series: Katie Janeway, MD and Suzanne Forrest, MD join us on OsteoBites to discuss results of a phase II trial of olaparib in combination with...
-
Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution
Osteosarcoma Webinar Series: Isidro Cortés-Ciriano will discuss his work studying how ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution.
-
osTEAo: Navigating Loss in the AYA Community
In this episode of osTEAo, Mia and Sammy — joined by Mackenzie and Alejandro — open up about the many forms of loss: losing friends, losing health, and losing parts of themselves as life shifts after cancer. They talk about how grief shows up in changing abilities, in memories, and in the quiet...
-
Synergy of ATM and PARP Inhibitors in Pediatric Osteosarcoma
Osteosarcoma Webinar Series: Janeala Morsby, PhD, a postdoctoral associate at St. Jude Children’s Research Hospital, discusses her OutSmarting Osteosarcoma funded work focused on exploring the mechanism of synergy of the dual inhibition of ATM and PARP for the treatment of pediatric osteosarcoma....
-
Comparative extracellular vesicle (EV) biomarkers for osteosarcoma risk and prognosis
Dr. Kelly Makielski and Dr. Jaime Modiano from the University of Minnesota join us on OsteoBites to discuss comparative extracellular vesicle (EV) biomarkers for osteosarcoma risk and prognosis. They are investigating extracellular vesicle (EV) transcriptomic profiles as minimally invasive...
-
osTEAo - Spooky Sarcoma Stories
This one’s for anyone who’s ever had a hospital night that felt straight out of a horror movie. In Spooky Sarcoma Stories, four young osteosarcoma survivors — Sammy, Alejandro, Inaaya, and Max swap their wildest, scariest, and most surreal treatment memories, like the time Alejandro thought the…
more -
Insights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer
Osteosarcoma Webinar Series: Alanna Church, MD, Associate Director, Laboratory for Molecular Pediatric Pathology at Boston Children's Hospital, Assistant Professor of Pathology at Harvard Medical School, and Conference Cochair joins us on OsteoBites to discuss insights and higlights from the AACR...
-
Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma
Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with…
more -
osTEAo - Turning Pain Into Purpose
In an inspirational episode of osTEAo, hosts Mia and Sammy honored the memory of their late friend and co-host, Camille Wahl. As one of the original founders of the podcast, Camille envisioned osTEAo as a space where adolescents and young adults affected by osteosarcoma could share their stories...
-
Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes
Osteosarcoma Webinar Series: Yanding Zhao, PhD to discuss how Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes. Osteosarcoma (OS) is notable for extreme chromosomal instability (CIN) and molecular heterogeneity, which have hindered...
-
Deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma
Bio Osteosarcoma Webinar Series: Brian Ladle, MD, PhD, Assistant Professor of Oncology and Pediatrics at The Johns Hopkins University School of Medicine, joins us on OsteoBites to discuss deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma. We have learned that...
-
osTEAo: The Fault in Our Scars - Dating & Cancer
Dating after cancer is… complicated. Scars, body changes, medical baggage - it’s not exactly the stuff of rom-coms. In The Fault in Our Scars, OsteoWarriors Elise, Gillian, Matthew, Mia, and Sammy, get real (and a little irreverent) about navigating first dates, deciding when to drop the “I had...
-
Clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group
Osteosarcoma Webinar Series: Amanda Marinoff, MD, a physician-scientist from UCSF will discuss clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group. Despite decades of research, osteosarcoma remains one of the few pediatric cancers without validated molecular...
-
Simultaneous targeting of CDK4/6 and BETs is independent of RB status in osteosarcoma
Osteosarcoma Webinar Series: Karen E. Pollok, PhD, and Pankita H. Pandya, PhD, from the Indiana University School of Medicine, join us on OsteoBites to discuss their work exploring CDK4/6i, particularly in the context of BET inhibition, as a therapeutic option for pediatric OS, regardless of RB...
-
osTEAo: When Positivity Silences Pain
In this powerful new episode of osTEAo, our AYA (Adolescent and Young Adult) cancer community gets real about toxic positivity - the idea that you have to "stay positive" no matter what you're going through, and while it's often well-meaning, it can leave patients feeling unseen, isolated, and...
-
Old drugs, new tricks? A novel immunomodulatory approach to relapsed osteosarcoma therapy
Kelly Faulk, MD, a pediatric oncologist at Children's Hospital Colorado Center for Cancer and Blood Disorders, joins us on OsteoBites to review the open phase 1/1b clinical trial evaluating the combination of losartan and sunitinib in the treatment of pediatric and adult patients with relapsed or...
-
Molecular subtyping of osteosarcoma, ecDNA and more
OsteoBites welcomes Yingqi Hua, MD from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine to discuss his work on molecular subtyping of osteosarcoma, ecDNA, and more. Dr. Hua has been engaged in basic and clinical research of malignant bone tumors for more than 10 years,...
-
osTEAo: What to Expect When You're Not Expecting
In this special Mother's Day edition of osTEAo, Mia, Sammy, and Elise open up about a topic that’s often left unspoken but is profoundly personal—fertility and infertility within the AYA cancer community. With honesty and vulnerability, they share their experiences navigating fertility challenges...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org
HOSTED BY
MIB Agents Osteosarcoma
Loading similar podcasts...
Frequently Asked Questions
How many episodes does MIB Agents OsteoBites and osTEAo have?
MIB Agents OsteoBites and osTEAo currently has 232 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is MIB Agents OsteoBites and osTEAo about?
Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org
How often does MIB Agents OsteoBites and osTEAo release new episodes?
MIB Agents OsteoBites and osTEAo publishes regularly with 232 episodes available. Check the episode list for the typical release schedule.
Where can I listen to MIB Agents OsteoBites and osTEAo?
You can listen to MIB Agents OsteoBites and osTEAo on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts MIB Agents OsteoBites and osTEAo?
MIB Agents OsteoBites and osTEAo is created and hosted by MIB Agents Osteosarcoma.
URL copied to clipboard!